Key Biosimilars Events of May 2026

Why It Matters

The wave of approvals deepens biosimilar competition, promising lower drug costs and broader treatment options while accelerating innovation through AI‑driven development partnerships.

Key Takeaways

• Bevqolva approved in Canada, expands Avastin biosimilar options
• Langlara becomes first interchangeable Lantus biosimilar in US
• Henlius gains FDA IND for Erbitux biosimilar HLX05‑N
• IQVIA adds AI tools to Kexing’s global biosimilar program
• Samsung Bioepis launches Eylea biosimilar Opuviz across EU

Pulse Analysis

The biosimilar landscape accelerated dramatically in May 2026, as regulators in North America, Europe and Asia granted approvals for a diverse slate of products. From oncology‑focused Bevqolva and HLX05‑N to diabetes‑targeted Langlara, Bysumlog and Dazparda, and ophthalmology agents like FYB203, Opuviz and Eyzanfy, the breadth of indications reflects a maturing pipeline that can erode the market share of originator biologics. This regulatory momentum is driven by streamlined pathways, robust comparative data, and heightened demand for cost‑effective therapies, especially in health‑system‑constrained environments.

Parallel to the approval surge, strategic collaborations are reshaping development speed and geographic reach. IQVIA’s expanded alliance with Kexing Biopharm leverages artificial‑intelligence platforms to optimize trial design, site selection and regulatory analytics, cutting timelines for multi‑product biosimilar programs. Likewise, partnerships such as Polpharma‑Tuteur for LATAM commercialization and Samsung Bioepis’s joint launch with NIPRO in Japan illustrate how companies are pooling expertise and market access to penetrate new regions quickly. These alliances not only distribute risk but also create scalable models that can be replicated across therapeutic classes.

For the industry, the combined effect of heightened competition and AI‑enhanced development promises tighter pricing, improved patient access, and a faster turnover of biosimilar entrants. Payers can negotiate more favorable contracts, while clinicians gain a broader therapeutic arsenal with comparable efficacy and safety. Looking ahead, the continued influx of biosimilars is likely to pressure originator manufacturers into price concessions and spur further innovation in delivery devices and combination therapies, reinforcing the biosimilar sector as a pivotal growth engine in global healthcare.